Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Likely Flaws Uncovered for LM-Method for Lyme Disease Detection

By LabMedica International staff writers
Posted on 12 Jul 2016
According to a new study, the recently developed modified microscopy technique “LM-method” of examining blood samples to help diagnose Lyme disease (and babesiosis) – is unable to distinguish infected patients from healthy controls, yielding many false-positive results.

While most people who contract Lyme disease recover quickly after antibiotic treatment, up to 20% of patients report persistent symptoms years after being told standard tests are negative for the disease. Interest in new diagnostic tests is therefore high.

The tick vector Ixodidae transmits Borrelia (bacterial causative agent of Lyme disease) as well as Babesia (parasitic protozoan causative agent of babesiosis). The new research follows up on a previous study suggesting that LM-method could detect active cases of disease caused by Borrelia and/or Babesia in just 1-2 days. Considerable publicity, and thereby patient demand, for this test in Norway continued despite that earlier studies did not include a control group and methods were not validated and ready for use in patients.

To investigate the reliability of the new test, Dr Audun Aase, from the Norwegian Institute of Public Health (Oslo, Norway), and colleagues collected blood samples from people who had been suffering from Lyme disease-like symptoms for several years and previously tested positive for Borrelia and/or Babesia infection using LM-method (21 people), and from healthy controls with no known history of tick bites (41 people). The samples were then masked and analyzed in independent laboratories using a range of diagnostic tests including the LM-method, conventional microscopy, genetic fingerprint testing (PCR), and serology.

The study indicated that LM-method results in high numbers of false positives: 14 (66%) patient-group samples and 35 (85%) control-group samples were judged positive for Borrelia and/or Babesia. However, only 1 sample (5%) of the patient-group and 8 samples (20%) of the control-group tested positive for Borrelia DNA by PCR. None of the samples were positive for Babesia DNA, and conventional microscopy did not identify Babesia in any of the samples. In conclusion, the structures interpreted as Borrelia and Babesia using LM-method could not be verified by PCR and the LM-method was thus falsified.

In an accompanying editorial commentary, Dr Ram B. Dessau, infectious diseases expert and senior consultant at Slagelse Hospital (Slagelse, Denmark), wrote: “I hope the study serves as a warning against non-validated microscopic procedures and helps prevent mismanagement of patients with chronic complaints, who are lured to seek improper diagnosis in the future.”

The study, by Aase A et al, was published online February 2016 in the journal Infectious Diseases.

Related Links:
Norwegian Institute of Public Health



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.